0001477960false--12-31Q120260.00010.00010.000128000000020000000200000000000000.0001700000000243632243632falsefalsefalsefalse50000000.000344296895561347950.000100014779602026-01-012026-03-310001477960srt:BoardOfDirectorsChairmanMemberus-gaap:SubsequentEventMember2026-05-060001477960srt:BoardOfDirectorsChairmanMemberus-gaap:SubsequentEventMember2026-05-012026-05-0600014779602026-02-012026-02-170001477960srt:BoardOfDirectorsChairmanMember2023-10-1200014779602026-03-100001477960srt:BoardOfDirectorsChairmanMember2026-03-310001477960us-gaap:SeriesAPreferredStockMember2026-01-012026-03-310001477960us-gaap:SeriesBPreferredStockMember2023-10-120001477960us-gaap:SeriesAPreferredStockMember2023-10-120001477960cctc:ConvertibleNotesPayableTwoMember2026-03-310001477960cctc:ConvertibleNotesPayableTwoMember2025-12-310001477960cctc:ConvertibleNotesPayableOneMember2025-12-310001477960cctc:ConvertibleNotesPayableOneMember2026-03-310001477960us-gaap:ConvertibleNotesPayableMember2025-12-310001477960us-gaap:ConvertibleNotesPayableMember2026-03-310001477960cctc:PromissoryNotesPayableFourtyOneMember2025-12-310001477960cctc:PromissoryNotesPayableFourtyOneMember2026-03-310001477960cctc:PromissoryNotesPayableFourtyMember2025-12-310001477960cctc:PromissoryNotesPayableFourtyMember2026-03-310001477960cctc:PromissoryNotesPayableThirtyNineMember2025-12-310001477960cctc:PromissoryNotesPayableThirtyNineMember2026-03-310001477960cctc:PromissoryNotesPayableThirtyEightMember2025-12-310001477960cctc:PromissoryNotesPayableThirtyEightMember2026-03-310001477960cctc:PromissoryNotesPayableThirtySevenMember2025-12-310001477960cctc:PromissoryNotesPayableThirtySevenMember2026-03-310001477960cctc:PromissoryNotesPayableThirtySixMember2025-12-310001477960cctc:PromissoryNotesPayableThirtySixMember2026-03-310001477960cctc:PromissoryNotesPayableThirtyFiveMember2025-12-310001477960cctc:PromissoryNotesPayableThirtyFiveMember2026-03-310001477960cctc:PromissoryNotesPayableThirtyFourMember2025-12-310001477960cctc:PromissoryNotesPayableThirtyFourMember2026-03-310001477960cctc:PromissoryNotesPayableThirtyThreeMember2025-12-310001477960cctc:PromissoryNotesPayableThirtyThreeMember2026-03-310001477960cctc:PromissoryNotesPayableThirtyTwoMember2025-12-310001477960cctc:PromissoryNotesPayableThirtyTwoMember2026-03-310001477960cctc:PromissoryNotesPayableThirtyOneMember2025-12-310001477960cctc:PromissoryNotesPayableThirtyOneMember2026-03-310001477960cctc:PromissoryNotesPayableThirtyMember2025-12-310001477960cctc:PromissoryNotesPayableThirtyMember2026-03-310001477960cctc:PromissoryNotesPayableTwentyNineMember2025-12-310001477960cctc:PromissoryNotesPayableTwentyNineMember2026-03-310001477960cctc:PromissoryNotesPayableTwentyEightMember2025-12-310001477960cctc:PromissoryNotesPayableTwentyEightMember2026-03-310001477960cctc:PromissoryNotesPayableTwentySevenMember2025-12-310001477960cctc:PromissoryNotesPayableTwentySevenMember2026-03-310001477960cctc:PromissoryNotesPayableTwentySixMember2026-03-310001477960cctc:PromissoryNotesPayableTwentySixMember2025-12-310001477960cctc:PromissoryNotesPayableTwentyFiveMember2026-03-310001477960cctc:PromissoryNotesPayableTwentyFiveMember2025-12-310001477960cctc:PromissoryNotesPayableTwentyFoureMember2026-03-310001477960cctc:PromissoryNotesPayableTwentyFoureMember2025-12-310001477960cctc:PromissoryNotesPayableTwentyThreeMember2026-03-310001477960cctc:PromissoryNotesPayableTwentyThreeMember2025-12-310001477960cctc:PromissoryNotesPayableTwentyTwoMember2026-03-310001477960cctc:PromissoryNotesPayableTwentyTwoMember2025-12-310001477960cctc:PromissoryNotesPayableTwentyOneMember2026-03-310001477960cctc:PromissoryNotesPayableTwentyOneMember2025-12-310001477960cctc:PromissoryNotesPayableTwentyMember2026-03-310001477960cctc:PromissoryNotesPayableTwentyMember2025-12-310001477960cctc:PromissoryNotesPayableNineteenMember2026-03-310001477960cctc:PromissoryNotesPayableNineteenMember2025-12-310001477960cctc:PromissoryNotesPayableEighteenMember2026-03-310001477960cctc:PromissoryNotesPayableEighteenMember2025-12-310001477960cctc:PromissoryNotesPayableSeventeenMember2026-03-310001477960cctc:PromissoryNotesPayableSeventeenMember2025-12-310001477960cctc:PromissoryNotesPayableSixteenMember2026-03-310001477960cctc:PromissoryNotesPayableSixteenMember2025-12-310001477960cctc:PromissoryNotesPayableFifteenMember2026-03-310001477960cctc:PromissoryNotesPayableFifteenMember2025-12-310001477960cctc:PromissoryNotesPayableFourteenMember2026-03-310001477960cctc:PromissoryNotesPayableFourteenMember2025-12-310001477960cctc:PromissoryNotesPayableThirteenMember2026-03-310001477960cctc:PromissoryNotesPayableThirteenMember2025-12-310001477960cctc:PromissoryNotesPayableTwelveMember2026-03-310001477960cctc:PromissoryNotesPayableTwelveMember2025-12-310001477960cctc:PromissoryNotesPayableElevenMember2026-03-310001477960cctc:PromissoryNotesPayableElevenMember2025-12-310001477960cctc:PromissoryNotesPayableTenMember2026-03-310001477960cctc:PromissoryNotesPayableTenMember2025-12-310001477960cctc:PromissoryNotesPayableNineMember2026-03-310001477960cctc:PromissoryNotesPayableNineMember2025-12-310001477960cctc:PromissoryNotesPayableEighthMember2026-03-310001477960cctc:PromissoryNotesPayableEighthMember2025-12-310001477960cctc:PromissoryNotesPayableSevenMember2026-03-310001477960cctc:PromissoryNotesPayableSevenMember2025-12-310001477960cctc:PromissoryNotesPayableSixMember2026-03-310001477960cctc:PromissoryNotesPayableSixMember2025-12-310001477960cctc:PromissoryNotesPayableFiveMember2026-03-310001477960cctc:PromissoryNotesPayableFiveMember2025-12-310001477960cctc:PromissoryNotesPayableFourMember2026-03-310001477960cctc:PromissoryNotesPayableFourMember2025-12-310001477960cctc:PromissoryNotesPayableThreeMember2026-03-310001477960cctc:PromissoryNotesPayableThreeMember2025-12-310001477960cctc:PromissoryNotesPayableTwoMember2026-03-310001477960cctc:PromissoryNotesPayableTwoMember2025-12-310001477960cctc:PromissoryNotesPayableOneMember2026-03-310001477960cctc:PromissoryNotesPayableOneMember2025-12-310001477960cctc:PromissoryNotesPayableMember2026-03-310001477960cctc:PromissoryNotesPayableMember2025-12-310001477960cctc:AssetPurchaseAgreementMember2026-01-012026-03-310001477960cctc:AssetPurchaseAgreementMember2026-02-012026-02-1700014779602024-06-090001477960cctc:StockPurchaseAgreementMember2024-06-012024-06-050001477960cctc:StockPurchaseAgreementMember2023-09-012023-09-1800014779602026-03-200001477960us-gaap:RetainedEarningsMember2026-03-310001477960us-gaap:AdditionalPaidInCapitalMember2026-03-310001477960us-gaap:CommonStockMember2026-03-310001477960us-gaap:RetainedEarningsMember2026-01-012026-03-310001477960us-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-310001477960us-gaap:CommonStockMember2026-01-012026-03-310001477960us-gaap:RetainedEarningsMember2025-12-310001477960us-gaap:AdditionalPaidInCapitalMember2025-12-310001477960us-gaap:CommonStockMember2025-12-3100014779602025-03-310001477960us-gaap:RetainedEarningsMember2025-03-310001477960us-gaap:AdditionalPaidInCapitalMember2025-03-310001477960us-gaap:CommonStockMember2025-03-310001477960us-gaap:RetainedEarningsMember2025-01-012025-03-310001477960us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-310001477960us-gaap:CommonStockMember2025-01-012025-03-3100014779602024-12-310001477960us-gaap:RetainedEarningsMember2024-12-310001477960us-gaap:AdditionalPaidInCapitalMember2024-12-310001477960us-gaap:CommonStockMember2024-12-3100014779602025-01-012025-03-310001477960us-gaap:SeriesBPreferredStockMember2025-12-310001477960us-gaap:SeriesBPreferredStockMember2026-03-310001477960us-gaap:SeriesAPreferredStockMember2025-12-310001477960us-gaap:SeriesAPreferredStockMember2026-03-310001477960cctc:PreferredStocksMember2025-12-310001477960cctc:PreferredStocksMember2026-03-3100014779602025-12-3100014779602026-03-3100014779602026-05-15iso4217:USDxbrli:sharesiso4217:USDxbrli:sharesxbrli:pure

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended: March 31, 2026

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Transition Period From ____________ to ____________.

LATAMED AI CORP.

(Exact name of registrant as specified in its charter)

Nevada

000-52543

26-3670551

(State or other jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

Av. Rómulo Gallegos con Av. Las Palmas

Edif. Torre Gerencial Los Andes

Caracas 1071, Venezuela

(Address of principal executive offices, including zip code.)

+1 787 476 2350

(Telephone number, including area code)

Securities registered under Section 12(b) of the Act: None

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☒

If an emerging growth company, indicate by check mark if the Company has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of May 15, 2026, the registrant had 56,134,795 shares of common stock issued and outstanding.

LATAMED AI CORP.

FORM 10-Q

Index

PART I. FINANCIAL INFORMATION

Item 1.	Condensed Financial Statements.	4
	CONDENSED BALANCE SHEETS	4
	CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)	5
	CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)	7
	CONDENSED STATEMENT OF CHANGES IN STOCKHOLDERS’ EQUITY (UNAUDITED)	6
	NOTES TO CONDENSED FINANCIAL STATEMENTS (UNAUDITED)	8
Item 2.	Management’s Discussion and Analysis of Financial Conditions and Results of Operations.	15
Item 3.	Quantitative and Qualitative Disclosures about Market Risk.	16
Item 4.	Controls and Procedures.	16

PART II. OTHER INFORMATION

Item 5.	Other Information.	17
Item 6.	Exhibits.	18

Table of Contents

SPECIAL NOTE REGARDING FORWARD-LOOKING INFORMATION

This quarterly report on Form 10-Q and other publicly available documents, including the documents incorporated herein by reference, contain, and our officers and representatives may from time to time make, “forward-looking” statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “believe,” “expect,” “future,” “likely,” “may,” “plan,” “seek,” “will” and similar references to future periods actions or results. Examples of forward-looking statements include our prospects for one or more future material transactions, potential sources of financing, and expenses for future periods.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements.

Any forward-looking statement made by us in this quarterly report on Form 10-Q is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Factors that could cause or contribute to such differences may include, but are not limited to, those described under the heading “Risk Factors” which may be included in the Company’s Registration Statement on Form 10 as previously filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this report. The Company undertakes no obligation to revise any forward-looking statements in order to reflect events or circumstances that may subsequently arise. Readers are urged to carefully review and consider the various disclosures made by the Company in this report and in the Company’s other reports filed with the Commission that advise interested parties of the risks and factors that may affect the Company’s business.

Table of Contents

PART I. FINANCIAL INFORMATION

Item 1. Condensed Financial Statements.

LataMed AI Corp.

(FKA Catalyst Crew Technologies Corp.)

CONDENSED BALANCE SHEETS

(Unaudited)

	March 31, 2026			December 31, 2025
ASSETS
Current assets
Cash	$	-		$	-
Total current assets		-			-

Intangible assets		7,824,000			-

Total assets		7,824,000			-

LIABILITIES AND STOCKHOLDERS' DEFICIT
Current liabilities
Accounts payable and accrued liabilities		260,352			235,923
Notes payable - related party		88,042			88,042
Notes payable		300,688			272,304
Convertible notes payable		34,591			34,591
Total current liabilities		683,673			630,860

Total liabilities		683,673			630,860

Stockholders' deficit

Preferred stock, $0.0001 par value, 280,000,000 shares authorized, 0 and 0 and shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively		-			-

Series A Preferred stock, $0.0001 par value, 20,000,000 shares authorized, 0 and 0 and shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively		-			-

Series B Preferred stock, $0.0001 par value, 20,000,000 shares authorized, 0 and 0 and shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively		-			-

Common stock, $0.0001 par value, 700,000,000 shares authorized, 243,632 and 243,632 and shares issued and outstanding as of March 31, 2026 and December 31, 2025		56,136			44,298
Additional paid in capital		36,737,790			28,925,628
Accumulated deficit		(29,653,599	)		(29,600,786	)
Total stockholders' deficit		7,140,327			(630,860	)

Total liabilities and stockholders' deficit	$	7,824,000		$	-

See accompanying notes to the financial statements

Table of Contents

LataMed AI Corp.

(FKA Catalyst Crew Technologies Corp.)

CONDENSED STATEMENTS OF OPERATIONS

(Unaudited)

	For the three months ended
	March 31, 2026			March 31, 2025

Revenue	$	-		$	-

Operating expenses
General and administrative		9,187			967
Professional fees		34,197			15,000
Total operating expenses		43,384			15,967

Loss from operations		(43,384	)		(15,967	)

Other income (expenses)
Interest expense		(9,429	)		(8,488	)
Total other expenses		(9,429	)		(8,488	)

Net loss before tax provision		(52,813	)		(24,455	)
Tax provision		-			-
Net loss	$	(52,813	)	$	(24,455	)

Net loss per common share - basic and diluted	$	(0.00	)	$	(0.00	)

Weighted average number of common shares outstanding - basic and diluted		56,134,795			29,276,895

See accompanying notes to the financial statements

Table of Contents

LataMed AI Corp.

(FKA Catalyst Crew Technologies Corp.)

CONDENSED STATEMENTS OF STOCKHOLDERS' DEFICIT

(Unaudited)

												Total
	Common Stock						Additional		Accumulated			Stockholders'
	Shares			Amount			Paid-in Capital		Deficit			Deficit
Balance, December 31, 2025		44,296,895			44,298			28,925,628		(29,600,786	)		(630,860	)
Shares issued for asset purchase agreement		12,000,000			12,000			7,812,000		-			7,824,000
Shares returned and cancelled		(162,100	)		(162	)		162		-			-
Net loss		-			-			-		(52,813	)		(52,813	)
Balance, March 31, 2026		56,134,795			56,136			36,737,790		(29,653,599	)		7,140,327

Balance, December 31, 2024		29,276,895			29,278			28,790,448		(29,393,301	)		(573,575	)
Net loss		-			-			-		(24,455	)		(24,455	)
Balance, March 31, 2025		29,276,895			29,278			28,790,448		(29,417,756	)		(598,030	)

See accompanying notes to the financial statements

Table of Contents

LataMed AI Corp.

(FKA Catalyst Crew Technologies Corp.)

CONDENSED STATEMENTS OF CASH FLOWS

(Unaudited)

	For the three months ended
	March 31, 2026			March 31, 2025
Cash Flows from Operating Activities
Net loss	$	(52,813	)	$	(24,455	)
Adjustments to reconcile net loss to net cash provided by operating activities:
Changes in assets and liabilities
Accounts payable and accrued liabilities		24,429			5,440
Net cash used in continuing operating activities		(28,384	)		(19,015	)

Cash Flows from Financing Activities:
Proceeds from notes payable		28,384			19,015
Net cash provided by financing activities		28,384			19,015

Net decrease in cash		-			-
Cash, beginning of period		-			-
Cash, end of period	$	-		$	-

Supplemental disclosure of cash flow information
Cash paid for interest	$	-		$	-
Cash paid for taxes	$	-		$	-

SUPPLEMENTARY DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:

Shares issued for intangible assets	$	-		$	875,000

See accompanying notes to the financial statements

Table of Contents

LataMed AI Corp.

(FKA Catalyst Crew Technologies Corp.)

NOTES TO FINANCIAL STATEMENTS

MARCH 31, 2026

NOTE 1 – NATURE OF BUSINESS AND OPERATIONS

Organization

LataMed AI Corp.(FKA Catalyst Crew Technologies Corp.) (the “Company or “CBBB”) was incorporated in the State of Nevada on September 11, 2008. At that time the primary business of the Company was to act as a global broker for business and private jets by connecting travelers (corporations, institutions and wealthy private individuals) with executive aircraft that are independently owned and operated by third party companies or individuals. On February 5, 2015, the Company changed its name to better reflect its anticipated new business direction. The Company had received approval of its Federal Permit to distribute alcoholic beverages, which would be accomplished, through its subsidiaries, Continental Beverage Inventory and Warehousing Ltd., and promotional activities through Continental Beverage Marketing and Promotion Inc. In early 2016, the Company abandoned its activities and ceased to operate.

On March 20, 2023, the “Company entered into an Asset Purchase Agreement by and among the Company, on the one hand and JT Technologies LLC (“JTLLC”) and Nitish Sharma, an individual and the sole managing member of JTLLC, on the other hand whereby the Company acquired various big data analytics related assets from the Seller for use in the gaming and gambling industry to analyze player behavior and fraud protection, among other similar information. Collectively, al intellectual property, proprietary and non-proprietary technology, know-how, and all other assets of the seller that maybe, directly, or indirectly, applied to big data analytics in the gaming and gaming industry are referred to hereinafter as the “Acquired Assets”. In exchange for the Acquired Assets, the Company issued 5,000,000 restricted shares of the 2. Buyer’s common stock to Seller.

On May 26, 2023, the Company changed its name to Blue Chip Technologies Corporation.

On September 18, 2023, the Company received notice of resignation from Mr. Andrew Gaudet from the positions of President, Chief Executive Officer, Treasurer, Chief Financial Officer, and Secretary. Mr. Gaudet retained his position as a member of the Company’s Board of Directors.

Effective the same day, the Company entered into an Executive Employment with Gurneet Kaur whereby Ms. Kaur agreed to serve as the Company’s Chief Executive Officer, President, Chief Financial Officer, Treasurer, Secretary, and as Chairman of the Company’s Board of Directors. On the same day, and pursuant to a Stock Purchase Agreement, Ms. Kaur acquired 48,944,965 shares of common stock from Nitish Sharma. Accordingly, Ms. Kaur now owns 72,944,965 restricted shares of our common stock, which represents approximately 66.53% of the total issued and outstanding shares of common stock.

On June 5, 2024, Ms. Kaur sold, by way of Stock Purchase Agreement (the “SPA”), 72,944,965 restricted shares of the Company’s common stock to Waqas Nakhwa. As a result of this SPA, Nakhwa is now deemed our controlling shareholder by virtue of his purchase of the Shares and holds 66.53% of our total voting stock.

Additionally, on June 7, 2024, the Company received notice of resignation from Ms. Kaur from the positions of President, Chief Executive Officer, Treasurer, Chief Financial Officer, Secretary and Director of the Company. Ms. Kaur’s resignation was not the result of any disagreements between Ms. Kaur and the Company relating to the Company’s operations, policies, or practices.

Effective immediately upon the resignation of Ms. Kaur, the Company’s Board of Directors appointed Mr. Nakhwa to serve as President, Chief Executive Officer, Treasurer, Chief Financial Officer, Secretary and Chairman of the Board of Directors to serve until the next annual meeting of the Company or until his respective successor is duly appointed. Mr. Nakhwa accepted all such appointments, effective as of June 7, 2024.

Table of Contents

On June 9, 2024, the Company entered into an Asset Transfer Agreement with Mr. Nakhwa pursuant to which Mr. Nakhwa assigned to the Company all of Mr. Nakhwa’s interest in Facial Recognition Technology (FRT) solutions and intellectual property associated therewith in exchange for $1.00.

On June 11, 2024, as a result of this change in management, the Company’s Board of Directors voted to (i) cease all prior operations of the Company involving big data analytics software for use in the gaming and financial technology industries, (ii) relinquish and disavow any and all interest in existing subsidiaries as of June 11, 2024 and (iii) amend the Company’s Articles of Incorporation to change the name of the Company to “Catalyst Crew Technologies Corp.” to more accurately reflect the Company’s new business direction. The Company will endeavor to affect the name change in near future or at such time management deems the name change appropriate. In the interim period until we affect this proposed name change, we will be operating as “Catalyst Crew Technologies.

On July 1, 2024, the Company’s Board of Directors approved a Change to its Articles of Incorporation, as amended, with the Secretary of Nevada to change the Company’s corporate name to “Catalyst Crew Technologies Corp.”

On February 17, 2026, the Company appointed Kevin Rodan Levy to serve as Chief Executive Officer, President, Chief Financial Officer, Secretary, Treasurer, and sole board member of the Company, effective immediately. On April 28, 2026, the Company filed a Certificate of Amendment with the Nevada Secretary of State changing the Company’s corporate name to "LataMed AI Corp.," which became effective upon filing.

On March 31, 2026, the Company's Board of Directors appointed Carlos Peña as Chief Financial Officer of the Company, effective immediately. Mr. Peña replaced Kevin Rodan Levy in the CFO role. Mr. Rodan Levy continues to serve as Chief Executive Officer, President, Secretary, Treasurer, and sole Director of the Company.

BASIS OF PRESENTATION

The accompanying financial statements have been prepared on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States. Management is of the opinion that all necessary adjustments have been made to make these interim financial statements not misleading.

NOTE 2 – GOING CONCERN

The accompanying financial statements have been prepared in US dollars and in accordance with accounting principles generally accepted in the United States (“GAAP”) on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. During three months ended March 31, 2026, the Company incurred net losses of $52,813 and accumulated deficits of $29,653,599. These conditions raise substantial doubt about the Company's ability to continue as a going concern.

We are entirely dependent on our ability to attract and receive funding from either the sale of securities or outside sources such as private investment or a strategic partner. We currently have no firm agreements or arrangements with respect to any such financing and there can be no assurance that any needed funds will be available to us on acceptable terms or at all. The inability to obtain sufficient funding of our operations in the future will restrict our ability to grow and reduce our ability to continue to conduct business operations. Our failure to raise additional funds will adversely affect our business, and may require us to suspend our operations, which in turn may result in a loss to the purchasers of our common stock. If we are unable to obtain necessary financing, we will likely be required to curtail our development plans. Any additional equity financing may involve substantial dilution to our then existing stockholders.

NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ significantly from those estimates.

Table of Contents

Cash and Cash Equivalents

For purposes of the statement of cash flows, the Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents to the extent the funds are not being held for investment purposes.

Stock-based compensation

The Company follows ASC 718-10, “Stock Compensation”, which addresses the accounting for transactions in which an entity exchanges its equity instruments for goods or services, with a primary focus on transactions in which an entity obtains employee services in share-based payment transactions. ASC 718-10 is a revision to SFAS No. 123, “Accounting for Stock-Based Compensation,” and supersedes Accounting Principles Board (“APB”) Opinion No. 25, “Accounting for Stock Issued to Employees,” and its related implementation guidance. ASC 718-10 requires measurement of the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award (with limited exceptions). Incremental compensation costs arising from subsequent modifications of awards after the grant date must be recognized.

Concentration of Credit Risk

The Company has no off-balance-sheet concentrations of credit risk such as foreign exchange contracts, options contracts or other foreign hedging arrangements. The Company maintains all of its cash balances with two financial institutions in the form of demand deposits.

Earnings per share

The Company follows ASC Topic 260 to account for the earnings per share. Basic earnings per common share (“EPS”) calculations are determined by dividing net income by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per common share calculations are determined by dividing net income by the weighted average number of common shares and dilutive common share equivalents outstanding. During periods when common stock equivalents, if any, are anti-dilutive they are not considered in the computation.

Revenue Recognition

The Company recognizes revenue from its contracts with customers in accordance with ASC 606 – Revenue from Contracts with Customers. The Company recognizes revenues when satisfying the performance obligation of the associated contract that reflects the consideration expected to be received based on the terms of the contract.

Revenue related to contracts with customers is evaluated utilizing the following steps: (i) Identify the contract, or contracts, with a customer; (ii) Identify the performance obligations in the contract; (iii) Determine the transaction price; (iv) Allocate the transaction price to the performance obligations in the contract; (v) Recognize revenue when the Company satisfies a performance obligation.

Fair Value of Financial Instruments

The Company measures fair value in accordance with ASC 820 - Fair Value Measurements. ASC 820 defines fair value and establishes a three-level valuation hierarchy for disclosures of fair value measurements. ASC 820 establishes a framework for measuring fair value in generally accepted accounting principles and expands disclosures about fair value measurements. To increase consistency and comparability in fair value measurements and related disclosures, ASC 820 establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three (3) broad levels. The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The three (3) levels of fair value hierarchy defined by ASC 820 are:

Level 1 - Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.

Level 2 - Inputs (other than quoted market prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life.

Level 3 - Inputs reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model. Valuation of instruments includes unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities.

Table of Contents

As defined by ASC 820, the fair value of a financial instrument is the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale, which was further clarified as the price that would be received to sell an asset or paid to transfer a liability (“an exit price”) in an orderly transaction between market participants at the measurement date

The reported fair values for financial instruments that use Level 2 and Level 3 inputs to determine fair value are based on a variety of factors and assumptions. Accordingly, certain fair values may not represent actual values of the Company’s financial instruments that could have been realized as of March 31, 2025 and December 31, 2024 or that will be recognized in the future, and do not include expenses that could be incurred in an actual settlement. The carrying amounts of the Company’s financial assets and liabilities, such as cash, accounts receivable, receivables from related parties, prepaid expenses and other, accounts payable, accrued liabilities, and related party and third-party notes payables approximate fair value due to their relatively short maturities. The Company’s notes payable approximates the fair value of such instrument based upon management’s best estimate of terms that would be available to the Company for similar financial arrangements on March 31, 2025 and December 31, 2024.

Recent Accounting Pronouncements

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The amendments in this ASU require disclosures, on an annual and interim basis, of significant segment expenses that are regularly provided to the chief operating decision maker (“CODM”), as well as the aggregate amount of other segment items included in the reported measure of segment profit or loss. This ASU requires that a public entity disclose the title and position of the CODM and an explanation of how the CODM uses the reported measure(s) of segment profit or loss in assessing segment performance and deciding how to allocate resources. This ASU is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years, with early adoption permitted. The amendments in this ASU should be applied retrospectively to all prior periods presented in the financial statements. The Company adopted the ASU and determined that its adoption did not have a material impact on the Company’s financial statements and related disclosures. As defined in the ASU, operating segments are components of an enterprise about which discrete financial information is regularly provided to the CODM in making decisions on how to allocate resources and assess performance for the organization. The Company operates and manages its business as one reportable and operating segment. The Company’s CODM is the Chief Executive Officer. The Company’s CODM reviews operating results to make decisions about allocating resources and assessing performance for the entire Company.

The Company does not believe that other standards, which have been issued but are not yet effective, will have a significant impact on its financial statements.

NOTE 4 – ASSET PURCHASE AGREEMENTS

On February 17, 2026, the Company entered into an Asset Purchase Agreement pursuant to which the Company acquired various proprietary assets and intellectual property for 12,000,000 restricted shares of common stock valued at $7,932,000.

The Company evaluated the Asset Purchase Agreement in accordance with ASC 805 – Business Combinations which notes the threshold requirements of a business combination that includes the expanded definition of a “business” and defines elements that are to be present to be determined whether an acquisition of a business occurred. No “activities” of the acquiree were acquired. Instead, the Company obtained control of a set of inputs (the acquired assets). Thus, the Company determined agreement is an acquisition of assets, not an acquisition of a business in accordance with ASC 805. Management evaluated the assets and determined the value to $7,932,000 as of March 31, 2026.

Table of Contents

NOTE 5 – NOTES PAYABLE

Promissory notes payable as of March 31, 2026 and December 31, 2025 consists of the following:

March 31, 2026		December 31, 2025
$	73,228	$	73,228
	2,500		2,500
	20,000		20,000
	4,571		4,571
	763		763
	7,341		7,341
	2,500		2,500
	5,000		5,000
	13,000		13,000
	8,000		8,000
	976		976
	12,000		12,000
	3,500		3,500
	5,000		5,000
	6,123		6,123
	5,000		5,000
	12,000		12,000
	1,341		1,341
	1,498		1,498
	5,300		5,300
	3,000		3,000
	1,791		1,791
	7,500		7,500
	4,500		4,500
	668		668
	6,500		6,500
	3,113		3,113
	250		250
	6,500		6,500
	10,000		10,000
	2,265		2,265
	980		980
	10,000		10,000
	3,874		3,874
	3,500		3,500
	5,000		5,000
	3,500		3,500
	1,832		1,832
	742		742
	7,148		7,148
	374		-
	28,010		-
$	300,688	$	272,304

During the three months ended March 31, 2026, the Company has issued various promissory notes amounting to $28,384 for general operating purposes. The notes carry an interest rate of 10% and are due upon demand.

During the three months ended March 31, 2026 and 2025, the Company recorded interest expense related to these notes of $5,488 and $4,547, respectively.

Table of Contents

NOTE 6 – CONVERTIBLE NOTES PAYABLE

Convertible notes payable as of March 31, 2026 and December 31, 2025 consists of the following:

March 31, 2026		December 31, 2025
$	15,487	$	15,487
	11,103		11,103
	8,000		8,000
$	34,591	$	34,591

During the three months ended March 31, 2026 and 2025, the Company recorded interest expense of $1,771 and $1,771, respectively.

NOTE 7 – RELATED PARTY TRANSACTIONS

As of March 31, 2026 and December 31, 2025, the Company had notes due to its majority shareholder, Kevin Rodan Levy, of $88,042 and $88,042, respectively. The notes carry an interest rate of 10% and are due upon demand.

During the three months ended March 31, 2026 and 2025, the Company recorded interest expense related to these notes of $2,171 and $2,171, respectively.

NOTE 8 – COMMITMENTS AND CONTINGENCIES

From time to time, the Company may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm business. Management is currently not aware of any such legal proceedings or claims that could have, individually or in the aggregate, a material adverse effect on our business, financial condition, or operating results.

NOTE 9 – STOCKHOLDERS’ EQUITY

As of March 31, 2026 and December 31, 2025, the Company had 56,134,795 and 44,296,895 shares of common stock issued and outstanding.

On July 1, 2024, the Company’s Board of Directors approved a One for Four Hundred Fifty (1-for-450) Reverse Stock Split of the issued and outstanding shares of Common Stock. The financial statements have been retroactively restated to reflect the split.

On October 12, 2023, the Board of Directors authorize an amendment to the articles of Incorporation to specifically increase the authorized shares to One Billion (1,000,000,000), consisting of; (i) Seven Hundred Million (700,000,000) shares of Common Stock, par value $0.0001 per share, Three Hundred Million (300,000,000) shares of preferred stock, par value $0.0001 per share which are issuable in one or more Series; to designate 10,000,000 preferred shares as Series A Preferred Stock and, (iv) to designate 10,000,000 preferred shares as Series B Preferred Stock.

Table of Contents

The Series A Preferred Stock shall rank senior to all Common Stock and any other class of securities that is specifically designated as junior to the Series A Preferred Stock however, does not have the right to vote. The Series A Preferred Stock is entitled to receive dividends from the Issuance Date thereof at the annual rate of three percent (3%) of the Original Issue Price, payable by the Board of Directors in quarterly installments. The Dividends shall cease to accrue on shares of Series A Preferred Stock on the date of any Conversion, as set forth herein. Each share of Series A Preferred Stock shall be convertible at the option of the holder after the One (1) Year anniversary of the Issuance Date, into a number of shares of Common Stock determined by dividing (i) the total number of Series A Preferred Shares being converted by (ii) the Conversion Price (the “Conversion Ratio”). The conversion price for the Series A Preferred Stock (the “Conversion Price”) shall be equal to $1.00 per share, which may be adjusted from time to time as hereinafter provided.

Series B Preferred Stock shall rank senior to all Common Stock and pari passu to the Series A Preferred Stock. Each share of Series B Preferred Stock shall be convertible at the option of the Holder thereof at any time, and from time to time, from and after the One (1) Year anniversary of the Issuance Date, into a number of shares of Common Stock determined by dividing (i) the total number of Series B Preferred Shares being converted by (ii) the Conversion Price The conversion price for the Series B Preferred Stock (the “Conversion Price”) shall be equal to $1.00 per share, which may be adjusted from time to time. Series B Preferred Stock shall not have the right to vote on any matters, questions, or proceedings of this Corporation. Holders of the Series B Preferred Stock must hold their Preferred shares for a period one (1) year from the Issuance Date prior to converting their Series B Preferred Shares to Common Shares.

Following the expiration of the Hold Period, the Corporation shall issue to the Holders bonus shares of the Corporation’s Common Stock in such amount to be the number of Series B Preferred held by each Holder by (ii)”). The Board of Directors shall have the authority, in its discretion, to grant the Bonus Shares to the Holders. Each Bonus Share shall constitute a transfer of a restricted Common Share to the Holder, without other payment therefor, as a bonus to the Holder.

On February 17, 2026, a shareholder returned and the Company cancelled 162,100 shares of common stock for no consideration.

On March 10, 2026, the Company issued 12,000,000 shares of common stock valued at $7,932,000 for certain intangible assets.

NOTE 10 – SUBSEQUENT EVENTS

In accordance with ASC Topic 855-10, the Company has analyzed its operations subsequent to March 31, 2026 through the date these financial statements were available to be issued and has identified the following material subsequent events:

On April 28, 2026, the Company filed a Certificate of Amendment to its Articles of Incorporation with the Nevada Secretary of State, changing the Company's corporate name from "Catalyst Crew Technologies Corp." to "LataMed AI Corp." The name change became effective upon filing.

On May 6, 2026, the Board of Directors of the Company approved the designation of a new series of preferred stock designated as the "Series C Voting Preferred Stock" and filed a Certificate of Designation with the Nevada Secretary of State. The principal terms include: (i) 5,000,000 authorized shares; (ii) voting rights of twenty (20) votes per share, voting together with the Company's common stock as a single class on all matters submitted to stockholders; (iii) non-convertible; (iv) liquidation preference senior to Common Stock and pari passu with any other series of Preferred Stock; and (v) non-redeemable. Protective provisions require approval of holders of a majority of outstanding Series C Preferred Stock prior to, among other things, creating or issuing any class of capital stock ranking senior to the Series C Preferred Stock, amending the terms of the Series C Preferred Stock in a manner adverse to its holders, or liquidating, dissolving, or winding up the Company.

Other than the foregoing, the Company has determined that it does not have any other material subsequent events to disclose in these financial statements.

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

FORWARD-LOOKING STATEMENTS

The following discussion may contain forward-looking statements regarding the Company, its business prospects and its results of operations that are subject to certain risks and uncertainties posed by many factors and events that could cause the Company’s actual business, prospects and results of operations to differ materially from those that may be anticipated by such forward-looking statements. These forward-looking statements reflect our view only as of the date of this report. The Company cannot guarantee future results, levels of activity, performance, or achievement. The Company does not undertake any obligation to update or correct any forward-looking statements.

Business Update

During the quarter ended March 31, 2026, the Company undertook a strategic transition toward the development of artificial intelligence-enabled healthcare technology solutions and related healthcare services infrastructure focused on Latin America.

On February 17, 2026, the Company entered into an Asset Purchase Agreement pursuant to which it acquired certain proprietary healthcare technology assets and intellectual property relating to an artificial intelligence-enabled healthcare analytics platform and a technology-enabled healthcare services coordination platform. The acquired assets include technologies intended to support data-driven healthcare analytics, patient monitoring, telehealth infrastructure, and related healthcare applications.

In connection with the Company’s strategic transition, the Company also established and organized operations through its wholly-owned Venezuelan subsidiary, Inversiones Long 33, C.A., which is intended to serve as the Company’s operating entity in Venezuela and support its broader Latin American business strategy.

During April 2026, certain intellectual property assets acquired by the Company were assigned to the subsidiary as part of an internal operational reorganization. Prior to such assignment, the subsidiary had no material operations, assets, liabilities, or standalone financial history.

Current activities are focused on organizational development, operational structuring, technology evaluation, regulatory planning, and business development initiatives related to the Company’s intended healthcare technology platform and services model.

Results of Operations for the Three Months Ended March 31, 2026 and 2025

Revenues

We had no revenue for three months ended March 31, 2026 and 2025.

Operating Expenses

Operating expenses increased to $43,384 for the three months ended March 31, 2026, from $15,967 for the same period ended March 31, 2025.

The increase in operating expenses is the result of additional professional fees incurred during the three months ended March 31, 2026.

Other Income (Expenses)

We had other expenses of $9,429 for the three months ended March 31, 2026, as compared with other expenses of $8,488 for the three months ended March 31, 2025. The increase in other expenses is the result of increased interest expense incurred during the three months ended March 31, 2026.

Net Loss

We recorded a net loss of $52,813 for the three months ended March 31, 2026, as compared with a net loss of $24,455 for the three months ended March 31, 2025.

Table of Contents

Liquidity and Capital Resources

Going concern – The accompanying financial statements have been prepared in US dollars and in accordance with accounting principles generally accepted in the United States (“GAAP”) on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. During three months ended March 31, 2026, the Company incurred net losses of $52,813 and accumulated deficits of $29,653,599. These conditions raise substantial doubt about the Company's ability to continue as a going concern.

As of March 31, 2026, we had total current assets of $0 and total assets in the amount of $7,824,000. Our total current liabilities as of March 31, 2026 were $683,673. We had a working capital deficit of $683,673 as of March 31, 2026, compared with a working capital deficit of $630,860 as of December 31, 2025.

Operating activities used $28,384 in cash for the three months ended March 31, 2026, as compared with $19,015 used for the three months ended March 31, 2025. Our negative operating cash flows for 2026 and 2025 was largely the result of our net loss for those quarters, mainly offset by changes in operating assets and liabilities.

We used no cash in investing activities for the three months ended March 31, 2026 and 2025.

Cash flow provided from financing activities was $28,384 for the three months ended March 31, 2026, as compared with $19,015 provided by cash flows for financing activities during the three months ended March 31, 2025.

Based upon our current financial condition, we do not have sufficient cash to operate our business at the current level for the next twelve months. We intend to fund operations through increased sales and debt and/or equity financing arrangements, which may be insufficient to fund expenditures or other cash requirements. We plan to seek additional financing in a private equity offering to secure funding for operations. There can be no assurance that we will be successful in raising additional capital.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

As a smaller reporting company, we are not required to provide the information required by this Item.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, the Company conducted an evaluation of the effectiveness of the design and operation of its disclosure controls and procedures, as such term is defined under Rule 13a-15(e) promulgated under the Exchange Act, as of March 31, 2026. Based on this evaluation, management concluded that our financial disclosure controls and procedures were not effective so as to timely record, process, summarize and report financial information required to be included on our SEC reports due to the Company’s limited internal resources and lack of ability to have multiple levels of transaction review. However, as a result of our evaluation and review process, management believes that the financial statements and other information presented herewith are materially correct.

Change in Internal Control Over Financial Reporting

The Company has not made any change in our internal control over financial reporting during the period ended March 31, 2026.

Table of Contents

PART II. OTHER INFORMATION

Item 5. Other Information.

During the quarter ended March 31, 2026, no director or officer of the Company adopted, modified, or terminated any Rule 10b5-1 trading arrangement or any non-Rule 10b5-1 trading arrangement, as each term is defined in Item 408(a) of Regulation S-K.

Table of Contents

ITEM 6 - EXHIBITS

Number Description of Exhibit

3.1		Articles of Incorporation, as amended (1)
3.2		Certificate of Amendment to the Articles of Incorporation of LataMed AI Corp.(2)
3.3		Certificate of Change Reflecting Reverse Stock Split(2)
3.4		Bylaws(1)
31.1		Certification of Principal Executive Officer Pursuant to Rule 13A-14(A) Under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.**
31.2		Certification of Principal Financial and Accounting Officer Pursuant to Rule 13A-14(A) Under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.**
32.1		Certification pursuant to Securities Exchange Act of 1934 Rule 13a-14(b) or 15d-14(b) and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes- Oxley Act of 2002. **
32.2		Certification pursuant to Securities Exchange Act of 1934 Rule 13a-14(b) or 15d-14(b) and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes- Oxley Act of 2002. **
101.INS		Inline XBRL Instance Document
101.SCH		Inline XBRL Taxonomy Extension Schema
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase
101.DEF		Inline XBRL Inline XBRL Taxonomy Extension Definition Linkbase
101.LAB		Inline XBRL Inline XBRL Taxonomy Extension Labels Linkbase
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase
104		Cover Page Interactive Data File (Embedded within the Inline XBRL document)

	(1)	Filed with the SEC on February 5, 2024 as an exhibit to our Registration Statement on Form 10-12G
	(2)	Filed with the SEC on August 16, 2024 as an exhibit to Current Report on Form 8-K
	**	Filed herewith

# The XBRL related information in Exhibit 101 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability of that section and shall not be incorporated by reference into any filing or other document pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing or document.

Table of Contents

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	LataMed AI Corp.

Date: May 20, 2026	By:	/s/ Kevin Rodan Levy
	Name:	Kevin Rodan Levy
	Title:	Chief Executive Officer (Principal Executive Officer)

Date: May 20, 2026	By:	/s/ Carlos Pena
	Name:	Carlos Pena
	Title:	Chief Financial Officer (Principal Financial and Accounting Officer)

LataMed AI Corp. 10-Q